Frederiksen H - Search Results

1

Health-related quality of life in adult primary immune thrombocytopenia.

Sestøl HG, Trangbæk SM, Bussel JB, Frederiksen H. Sestøl HG, et al. Among authors: frederiksen h. Expert Rev Hematol. 2018 Dec;11(12):975-985. doi: 10.1080/17474086.2018.1548930. Epub 2018 Nov 27. Expert Rev Hematol. 2018. PMID: 30444433 Review.

2

[The pathogenesis of primary immune thrombocytopenia].

Gudbrandsdottir S, Frederiksen H, Birgens HS, Nielsen CH, Nielsen OJ, Stentoft J, Hasselbalch HC. Gudbrandsdottir S, et al. Among authors: frederiksen h. Ugeskr Laeger. 2011 Jan 24;173(4):274-7. Ugeskr Laeger. 2011. PMID: 21262172 Danish.

3

Risk and prognosis of adult primary immune thrombocytopenia.

Frederiksen H, Christiansen CF, Nørgaard M. Frederiksen H, et al. Expert Rev Hematol. 2012 Apr;5(2):219-28. doi: 10.1586/ehm.12.7. Expert Rev Hematol. 2012. PMID: 22475290 Review.

4

Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study.

Frederiksen H, Maegbaek ML, Nørgaard M. Frederiksen H, et al. Br J Haematol. 2014 Jul;166(2):260-7. doi: 10.1111/bjh.12869. Epub 2014 Apr 2. Br J Haematol. 2014. PMID: 24690142 Free article.

5

Bone morbidity in chronic myeloproliferative neoplasms.

Farmer S, Ocias LF, Vestergaard H, Broesby-Olsen S, Hermann AP, Frederiksen H. Farmer S, et al. Among authors: frederiksen h. Expert Rev Hematol. 2015 Aug;8(4):447-56. doi: 10.1586/17474086.2015.1053456. Epub 2015 Jun 2. Expert Rev Hematol. 2015. PMID: 26036168 Review.

6

Rituximab for adult primary immune thrombocytopenia.

Frederiksen H. Frederiksen H. Lancet Haematol. 2015 Feb;2(2):e52-3. doi: 10.1016/S2352-3026(15)00006-X. Epub 2015 Feb 5. Lancet Haematol. 2015. PMID: 26687609 No abstract available.

7

Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia.

Frederiksen H, Ghanima W. Frederiksen H, et al. Eur J Intern Med. 2017 Jan;37:e23-e25. doi: 10.1016/j.ejim.2016.09.001. Epub 2016 Sep 12. Eur J Intern Med. 2017. PMID: 27633568 No abstract available.

8

Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide.

Mortensen TB, Frederiksen H, Marcher CW, Preiss B. Mortensen TB, et al. Among authors: frederiksen h. BMJ Case Rep. 2017 Jan 4;2017:bcr2016215888. doi: 10.1136/bcr-2016-215888. BMJ Case Rep. 2017. PMID: 28052942 Free PMC article.

9

A systematic review of health-related quality of life in longitudinal studies of myeloma patients.

Nielsen LK, Jarden M, Andersen CL, Frederiksen H, Abildgaard N. Nielsen LK, et al. Among authors: frederiksen h. Eur J Haematol. 2017 Jul;99(1):3-17. doi: 10.1111/ejh.12882. Epub 2017 Apr 25. Eur J Haematol. 2017. PMID: 28322018 Review.

10

Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients.

Nielsen LK, Klausen TW, Jarden M, Frederiksen H, Vangsted AJ, Do T, Kristensen IB, Frølund UC, Andersen CL, Abildgaard N, Gregersen H. Nielsen LK, et al. Among authors: frederiksen h. Eur J Haematol. 2019 Jan;102(1):70-78. doi: 10.1111/ejh.13175. Epub 2018 Oct 29. Eur J Haematol. 2019. PMID: 30230047 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

451 results

Search Page